The ExCEEd Orphan announces its cooperation with Hansa Biopharma in commercialization of IDEFIRIX TM (Imlifidase) in the Czech Republic. Idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. ExCEEd Orphan is proud to bring such innovative therapy to those patients with limited possibilites for kidney transplantation.
